NEW YORK (GenomeWeb News) – Roche Applied Science and Exiqon today announced a joint marketing agreement covering Roche's RealTime ready assays and Exiqon's miRCURY LNA Universal RT microRNA pPCR system.
Financial terms were not disclosed.
Roche's RealTime assays are based on Exiqon's Universal ProbeLibrary technology and offer "maximized testing efficiency," Exiqon said in a statement. In 2008, the two firms inked a deal under which Roche was given co-exclusive rights to use Exiqon's Universal ProbeLibrary of LNA oligonucleotides to develop and manufacture its RealTime ready qPCR assays.
Exiqon said today that its LNA-enhanced PCR primers have "exceptional" sensitivity and specificity, "enabling accurate quantification of very low amounts of microRNA obtained from difficult samples," including frozen formalin paraffin-embedded tissue, serum, plasma, and laser capture microscopy.